Clinically validated data demonstrate greater than 93% concordance in detecting EGFR mutation with tissue biopsy in 74 patients diagnosed with lung cancer
David F. Hale and Ivor Royston, M.D. Join Biocept Board The Board of Biocept, Inc. announced today that David F. Hale has joined the Board as Executive Chairman and Ivor Royston, M.D. as a Director. Mr. Hale and Dr. Royston first worked together at Hybritech, San Diego’s first biotech company, of
University of Colorado-affiliated scientific leader to collaborate on assays for biopharmaceutical partners SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer,
SAN DIEGO --(BUSINESS WIRE)--Mar. 24, 2023-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical trial with the Company’s proprietary cerebrospinal fluid assay CNSide (NCT05414123).
SAN DIEGO --(BUSINESS WIRE)--Sep. 21, 2023-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal
Expands intellectual property to 27 issued patents globally for highly sensitive methods of detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs) SAN DIEGO , July 31, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of
Expands Biocept's intellectual property portfolio to 21 issued patents for its highly sensitive methods of detecting cancer biomarkers on circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA)
Study data further support the clinical utility and validation of Biocept's CTC and ctDNA tests to profile and monitor biomarker status in patients diagnosed with cancer
Data highlight the ability of Biocept's patented and proprietary circulating tumor DNA assays to consistently detect actionable biomarkers from the blood of patients diagnosed with lung cancer at a mutant allele frequency as low as 0.01% SAN DIEGO , Aug. 22, 2019 /PRNewswire/ -- Biocept, Inc .
